Moreover, studies have reported that high ERCC1 expression is significantly associated with enhanced chemotherapy response induced by 5-FU and cisplatin, suggesting that ERCC1 expression can be used as a biomarker to predict the efficacy of 5-FU and cisplatin chemotherapy for HNSCC (33). Here, ERCC1 is linked to head and neck squamous cell carcinoma.